{"DataElement":{"publicId":"5977098","version":"1","preferredName":"Disease or Disorder Myelodysplastic Syndrome IPPS Category","preferredDefinition":"A response for the score or categorization of myelodysplasia syndrome progression risk.","longName":"DZ_MDS_IPPS_CAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5981651","version":"1","preferredName":"Disease or Disorder Myelodysplastic Syndrome","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","longName":"2404658v1.0:5981649v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5981649","version":"1","preferredName":"Myelodysplastic Syndrome","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","longName":"C3247","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"598D6A50-32A1-7DDF-E053-F662850AECC0","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"598D6A50-32B2-7DDF-E053-F662850AECC0","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released.; 9/19/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5977092","version":"1","preferredName":"International Prognostic Scoring System for Myelodysplastic Syndromes Category","preferredDefinition":"A system for scoring myelodysplasia syndrome progression risk, based on a combination of: percentage of blast cells in the bone marrow, the presence and severity of specific cytogenetic abnormalities, and the number of cytopenias in the peripheral blood._A grouping of items based on some commonality or by user defined characteristics.","longName":"5977092v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Greater than or equal to 2.5","valueDescription":"IPSS Risk Score Greater than or Equal to 2.5","ValueMeaning":{"publicId":"5981646","version":"1","preferredName":"IPSS Risk Score Greater than or Equal to 2.5","longName":"5981646","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score greater than or equal to 2.5, corresponding to high risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Score Greater than or Equal to 2.5","conceptCode":"C139300","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score greater than or equal to 2.5, corresponding to high risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-D00D-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598DF080-3E88-5B6F-E053-F662850ABAC6","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"Low","valueDescription":"IPSS Risk Category Low","ValueMeaning":{"publicId":"5981639","version":"1","preferredName":"IPSS Risk Category Low","longName":"5981639","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low likelihood for progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Category Low","conceptCode":"C139301","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low likelihood for progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CF0A-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CF23-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"Intermediate-1","valueDescription":"IPSS Risk Category Intermediate-1","ValueMeaning":{"publicId":"5981640","version":"1","preferredName":"IPSS Risk Category Intermediate-1","longName":"5981640","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low-intermediate likelihood for progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Category Intermediate-1","conceptCode":"C139302","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low-intermediate likelihood for progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CF2F-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CF48-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"Intermediate-2","valueDescription":"IPSS Risk Category Intermediate-2","ValueMeaning":{"publicId":"5981641","version":"1","preferredName":"IPSS Risk Category Intermediate-2","longName":"5981641","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high-interdemiate likelihood for progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Category Intermediate-2","conceptCode":"C139303","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high-interdemiate likelihood for progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CF54-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CF6D-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"High","valueDescription":"IPSS Risk Category High","ValueMeaning":{"publicId":"5981642","version":"1","preferredName":"IPSS Risk Category High","longName":"5981642","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high likelihood for progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Category High","conceptCode":"C139304","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high likelihood for progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CF79-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CF92-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"0","valueDescription":"IPSS Risk Score 0","ValueMeaning":{"publicId":"5981643","version":"1","preferredName":"IPSS Risk Score 0","longName":"5981643","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0, corresponding to low risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Score 0","conceptCode":"C139297","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0, corresponding to low risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CF9E-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CFB7-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"0.5 to 1.0","valueDescription":"IPSS Risk Score 0.5 to 1.0","ValueMeaning":{"publicId":"5981644","version":"1","preferredName":"IPSS Risk Score 0.5 to 1.0","longName":"5981644","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0.5 to 1.0, corresponding to intermediate-1 risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Score 0.5 to 1.0","conceptCode":"C139298","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0.5 to 1.0, corresponding to intermediate-1 risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CFC3-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-CFDC-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"},{"value":"1.5 to 2.0","valueDescription":"IPSS Risk Score 1.5 to 2.0","ValueMeaning":{"publicId":"5981645","version":"1","preferredName":"IPSS Risk Score 1.5 to 2.0","longName":"5981645","preferredDefinition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 1.5-2.0, corresponding to intermediate-2 risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IPSS Risk Score 1.5 to 2.0","conceptCode":"C139299","definition":"An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 1.5-2.0, corresponding to intermediate-2 risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"598BE41C-CFE8-06C9-E053-F662850A0D13","latestVersionIndicator":"Yes","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598BE41C-D001-06C9-E053-F662850A0D13","beginDate":"2017-09-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5977662","version":"1","preferredName":"International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes Category","preferredDefinition":"A system for scoring myelodysplasia syndrome progression risk, based on a combination of: percentage of blast cells in the bone marrow, the presence and severity of specific cytogenetic abnormalities, and the number of cytopenias in the peripheral blood.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C84350:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes","conceptCode":"C84350","definition":"A system for scoring myelodysplasia syndrome progression risk, based on a combination of: percentage of blast cells in the bone marrow, the presence and severity of specific cytogenetic abnormalities, and the number of cytopenias in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59000E35-6D91-444F-E053-F662850A64E9","latestVersionIndicator":"Yes","beginDate":"2017-09-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-12","modifiedBy":"ONEDATA","dateModified":"2017-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58EC3E06-922D-6524-E053-F662850ACC19","latestVersionIndicator":"Yes","beginDate":"2017-09-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-11","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; 9/19/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"IPSS","type":"Preferred Question Text","description":"IPSS","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58EEA2A3-B4B8-7D45-E053-F662850AEA9C","latestVersionIndicator":"Yes","beginDate":"2017-09-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-11","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; 9/11/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}